Clinical trial
Comparison of Cerebrolysin and Donepezil: A Randomized, Double-blind, Controlled Trial on Efficacy and Safety in Patients With Mild to Moderate Alzheimer's Disease
NCT01822951 is registered in ClinicalTrials.gov with Ever Neuro Pharma GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Comparison of Cerebrolysin and Donepezil: A Randomized, Double-blind, Controlled Trial on Efficacy and Safety in Patients With Mild to Moderate Alzheimer's Disease
- Lead sponsor
- Ever Neuro Pharma GmbH
- Phase
- Phase 4
- Overall status
- Withdrawn
- Start date
- Not reported
- Completion date
- December 31, 2016
- Enrollment
- 0 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.